Research programme: anti-cancer and anti-inflammation therapeutics - Curadev Pharma

Drug Profile

Research programme: anti-cancer and anti-inflammation therapeutics - Curadev Pharma

Latest Information Update: 29 May 2015

Price : $50

At a glance

  • Originator Curadev Pharma
  • Developer Curadev Pharma; Roche
  • Class Small molecules
  • Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors; Phosphotransferase inhibitors; Transcription factor modulators; Tryptophan oxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Haematological malignancies; Solid tumours
  • Research Immunological disorders

Most Recent Events

  • 23 Apr 2015 Curadev Pharma and Roche entered into collaboration to co-develop IDO 1 and TDO inhibitors in India for Cancer
  • 20 Apr 2015 Preclinical trials in Cancer in India (unspecified route)
  • 20 Apr 2015 Early research in Immunological disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top